News & Publications

News

Deals & Cases

CHF 15.5 Million financing round in Swiss Startup Oculis SA

17 January 2019 –

The Tekla Funds (Healthcare, Life Sciences) invested in Oculis SA as part of a CHF 15.5 equity financing round.

Oculis SA is biopharmaceutical Swiss Startup company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases in order to improve the sight and the lives of patients worldwide.

Each Tekla Fund is a non-diversified closed-end fund, the stock of which is traded on the New York Stock Exchange. The Tekla Funds are managed by Tekla Capital Management LLC, a registered investment advisor based in Boston, Massachusetts with approximately USD 3.3 billion of assets under management. They predominately invest in the securities of public and private healthcare companies.

Walder Wyss acted as legal counsel as to Swiss law to the Tekla Funds. The team was led by Alex Nikitine (Partner, Corporate/M&A, Capital Markets) and further included Marion Bähler (Associate, Corporate/M&A) and Dimitrios Berger (Associate, Corporate/M&A).

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.